PT-141 (bremelanotide) is a melanocortin agonist that activates MC4R in hypothalamic arousal circuits, so it acts centrally on desire rather than on blood flow the way PDE5 inhibitors do. It is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women, and it began as a men's erectile-dysfunction candidate. Different mechanism, different problem, which is why the two classes are studied side by side.
- FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder.Kingsberg 2019
- Activates MC4R in hypothalamic arousal circuits: it targets desire in the brain, not the plumbing.PubMed: bremelanotide
- It began as a men's erectile-dysfunction candidate and acts through a different pathway than PDE5 inhibitors; the literature describes additive rather than duplicated effects, alongside additive transient blood-pressure and heart-rate effects that make concurrent peak exposure something the source explicitly flags to avoid.Wessells 2000
- Honest number from the label: focal hyperpigmentation ran about 1% with intermittent use but reached 38% under continuous daily exposure, which is a strong argument against scheduled use in study design.FDA Vyleesi label